Archive: treatment
-
Aducanumab (AduhelmTM) – the first disease-modifying treatment for Alzheimer’s disease approved by the US Food and Drug Administration, 7 June 2021
Availability of Aduhelm remains unclear Coverage by Medicare and other third-party payers unknown More information to follow R. Scott Turner, PhD, MD, and the Memory Disorders Program On
Category: News
-
Where Are We in the Search for Better Treatments?
Alzheimer’s Talks host Meryl Comer speaks with one of the nation’s leading Alzheimer’s disease researchers, Dr. R. Scott Turner, director of the Georgetown University Memory Disorders Program, about the current Alzheimer’s drug pipeline and related questions of diagnosis and prevention methods.
Category: News